Showing results (71-80 of 112) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)Nancy U Lin, Hao Guo, Jeffrey T Yap, et al.Cancer Cell|March 14, 2007
Molecular definition of breast tumor heterogeneityMichail Shipitsin, Lauren L Campbell, Pedram Argani, et al.The Journal of Clinical Investigation|August 14, 2012
A metabolic prosurvival role for PML in breast cancerArkaitz Carracedo, Dror Weiss, Amy K Leliaert, et al.Plos Genetics|November 19, 2010
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesisMark M Pomerantz, Yashaswi Shrestha, Richard J Flavin, et al.The American Journal of Surgical Pathology|June 14, 2013
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistryDavid J Dabbs, Stuart J Schnitt, Felipe C Geyer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancerDaniel P Silver, Andrea L Richardson, Aron C Eklund, et al.Proceedings of the National Academy of Sciences of the United States of America|September 11, 2008
Cell type-specific DNA methylation patterns in the human breastNoga Bloushtain-Qimron, Jun Yao, Eric L Snyder, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L Telli, Kirsten M Timms, Julia Reid, et al.Nature Genetics|August 2, 2011
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesisJason W Locasale, Alexandra R Grassian, Tamar Melman, et al.Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.Pageof 12